πŸ‡ΊπŸ‡Έ FDA
Patent

US 7365165

IL-1 antagonist formulations

granted A61KA61K38/1709A61K38/2006

Quick answer

US patent 7365165 (IL-1 antagonist formulations) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/1709, A61K38/2006, A61K47/10, A61K47/183